Axonics Modulation Technologies, which is commercializing a neural implant for overactive bladder and incontinence, raised $120 million by offering 8 million shares at $15, the midpoint of the $14 to ...

Barely a month after winning FDA clearance for its long-lasting implant to treat bladder dysfunction, Axonics is wasting no time in bringing the device to the masses. The Southern California-based ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

An Axonics sacral neuromodulation system sends electrical signals to nerves in the spinal cord to help regulate the bladder and bowels Device maker Axonics Inc. says its newest system designed to ...

Axonics Modulation Technologies has pulled in a meaty IPO as it looks to compete with medical technology major Medtronic for its neuromodulation device in overactive bladder (OAB). The IPO window has ...

Boston Scientific Corporation plans to acquire Axonics, Inc. for $3.7 billion in cash to expand its urology offerings with Axonics' innovative urinary and bowel disorder treatments. Axonics, founded ...

Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...

Boston Scientific Corporation (NYSE:BSX) has agreed to acquire Axonics Inc (NASDAQ: AXNX) for $71 in cash per share, representing an enterprise value of approximately $3.4 billion and an equity value ...

Medical device maker Boston Scientific said on Monday it had agreed to buy Axonics for $3.7 billion, gaining access to devices used to improve bladder function. The deal marks Boston Scientific's ...